Studies on IdyllaTM MSI and RAS liquid biopsy tests to be presented at ESMO congress
(WorldNews Belgium)

PRESS RELEASE 19 October 2018, 07:00 CEST Studies on IdyllaTM MSI and RAS liquid biopsy tests to be presented at ESMO congress Mechelen, Belgium, 19 October 2018 - Biocartis Group NV (the `Company` or `Biocartis`), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces that two studies, one treatment outcome study1 on the IdyllaTM ctKRAS and ctNRAS-BRAF Mutation Tests (CE-IVD) and one2 on the performance of the prototype IdyllaTM MSI test,have been selected for presentation at the renowned European Society for Medical Oncology (ESMO) congress. The ESMO congress is considered the most influential annual meeting for oncology professionals in Europe and takes place...